- Report
- April 2025
- 175 Pages
Global
From €3956EUR$4,490USD£3,409GBP
Sucraid is a brand of enzyme replacement therapy used to treat endocrine and metabolic disorders. It is a recombinant human enzyme that is used to replace the missing enzyme in patients with a deficiency. The enzyme is used to break down carbohydrates, proteins, and fats in the body, allowing for proper digestion and absorption of nutrients. It is also used to treat a variety of other conditions, including cystic fibrosis, pancreatic insufficiency, and short bowel syndrome.
The Sucraid market is a niche market within the larger endocrine and metabolic disorders drugs market. It is a specialized market that focuses on providing treatments for patients with enzyme deficiencies. The market is highly competitive, with a number of companies offering different products and services.
Some of the companies in the Sucraid market include AbbVie, Amicus Therapeutics, BioMarin Pharmaceuticals, and Shire. These companies offer a variety of products and services, including enzyme replacement therapies, nutritional supplements, and other treatments. Show Less Read more